gms | German Medical Science

27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Liga zur Bekämpfung des hohen Blutdrucks – Deutsche Hypertonie Gesellschaft e. V.

26. bis 29.11.2003, Bonn

Antihypertensive therapy with a new third generation calcium antagonist in patients with concomitant diseases

Meeting Abstract (Hypertonie 2003)

  • presenting/speaker A. Marx - Berlin-Chemie AG (Berlin, D)
  • A. Lichtenthal - Berlin-Chemie AG (Berlin, D)
  • C. Milbredt - Berlin-Chemie AG (Berlin, D)
  • R. Ott - Berlin-Chemie AG (Berlin, D)
  • B. Zegenhagen-Phiong - Berlin-Chemie AG (Berlin, D)
  • S. Tegeler - Berlin-Chemie AG (Berlin, D)
  • R. Agrawal - Berlin-Chemie AG (Berlin, D)

Hypertonie 2003. 27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Bonn, 26.-29.11.2003. Düsseldorf, Köln: German Medical Science; 2004. Doc03hochP15

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 11. November 2004

© 2004 Marx et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.




In randomized controlled trials lercanidipine was well tolerated, with very few treatment-related adverse events typical of dihydropyridine calcium antagonists (e.g. ankle oedema, flushing and headache). To evaluate the

efficacy and tolerability of lercanidipine in daily clinical practice 32.345 patients were examined in a post marketing surveillance study over 6 weeks.


Patients with mild to moderate essential hypertension received lercanidipine 10 mg once daily with a 6-week follow-up. 32.345 patients were included into this multicenter observational study (mean +/- SD age 60.0 +/- 12.3 years, 51.0% women and body mass index 27.7 +/- 3.9 kg/m2).

During the 6-week follow-up the blood pressure and heart rate were measured at baseline, after 3 weeks (+/- 1 week) and after 6 weeks (+/- 1 week).


Patients had concomitant diseases, such as lipid metabolism disorders (35.8%), diabetes mellitus (23.0%), coronary heart disease (21.9%), heart failure (10.4%) and others (19.4%). For these concomitant diseases the patients received additional drugs in 62.2 percentage of cases.

Patients with at least one concomitant disease had a somewhat higher mean baseline value of systolic blood pressure (162.4 +/- 17.2 mmHg) and lower baseline value of diastolic blood pressure (93.1 +/- 9.7 mmHg) as patients without concomitant disease (159.7 +/- 16.2 mmHg/ 93.5 +/- 9.4). In patients with concomitant diseases after 6 weeks, the decrease in systolic blood pressure was a little more pronounced (141.5 +/- 12.3 mmHg) than in patients without concomitant diseases (139.0 +/- 11.1 mmHg). Concomitant medication was reported for a total of 20.127 patients (62.2%).

For all patients after 6 weeks the systolic blood pressure (BP) reduced from 161.5 +/- 16.9 to 140.5 +/- 11.8 mmHg, the diastolic blood pressure reduced from 93.2 +/- 9.6 mmHg to 83.0 +/- 7.0 mmHg.

The mean heart rate did not change (from 76.3 beats/min to 74.3 beats/min). The overall incidence of adverse events was < 1%, of which the most frequent were flushing, headache, and leg oedema.


In this multicenter observational study patients with concomitant diseases tolerated lercanidipin well and showed a pronounced blood pressure reduction.